Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson’s Disease Patients over a Decade in Singapore

Table 2

Drug combinations for patients on dual/triple therapy in 2007 and 2017.

Drug combinations	n = 34
Dual therapy
LD + DA	2
LD + MAOBI	10
LD + anticholinergic	2
DA + MAOBI	10
DA + anticholinergic	4
MAOBI + anticholinergic	5
Triple therapy
LD + DA + MAOI	1

DA, dopamine agonist; LD, levodopa; MAOBI, monoamine oxidase type B inhibitor.